Vericel Corp Ord Cash Flow Conversion Efficiency
Vericel Corp Ord cash flow conversion efficiency. Based on the latest financial reports, Vericel Corp Ord (VCEL) has a cash flow conversion efficiency ratio of 0.042x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($15.01 Million) by net assets ($354.64 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Vericel Corp Ord (1995–2025)
Cash flow conversion efficiency of Vericel Corp Ord from 1995 to 2025. This chart illustrates how Vericel Corp Ord's cash flow conversion efficiency has evolved over time, based on yearly financial data. View VCEL share price today for real-time trading data and today's change.
Vericel Corp Ord Cash Flow Conversion Ratio Explained
Vericel Corp Ord cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Vericel Corp Ord Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vericel Corp Ord ranked by their cash flow conversion efficiency. Also see VCEL stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Believe SAS
PA:BLV
|
0.049x |
|
Milkyway Chemical Supply Chain Service Co Ltd
SHG:603713
|
-0.055x |
|
Lier Chemical Co Ltd
SHE:002258
|
0.070x |
|
Anhui Jinhe Industrial Co Ltd
SHE:002597
|
0.036x |
|
Sichuan Injet Electric Co Ltd
SHE:300820
|
0.035x |
|
Spartan Delta Corp
TO:SDE
|
0.139x |
|
Iluka Resources Ltd
AU:ILU
|
-0.039x |
|
Ningbo PIA Automation Holding Corp. A
SHG:688306
|
N/A |
Annual Cash Flow Conversion Efficiency for Vericel Corp Ord (1995–2025)
The table below shows the annual cash flow conversion efficiency of Vericel Corp Ord from 1995 to 2025. Review Vericel Corp Ord free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $354.64 Million | $51.91 Million | 0.146x | -26.52% |
| 2024-12-31 | $291.97 Million | $58.16 Million | 0.199x | +27.47% |
| 2023-12-31 | $225.95 Million | $35.31 Million | 0.156x | +69.89% |
| 2022-12-31 | $192.27 Million | $17.69 Million | 0.092x | -46.00% |
| 2021-12-31 | $170.46 Million | $29.04 Million | 0.170x | +30.17% |
| 2020-12-31 | $134.26 Million | $17.57 Million | 0.131x | +302.42% |
| 2019-12-31 | $111.09 Million | $-7.18 Million | -0.065x | -1504.40% |
| 2018-12-31 | $102.23 Million | $-412.00K | -0.004x | +99.31% |
| 2017-12-31 | $22.54 Million | $-13.18 Million | -0.585x | +27.35% |
| 2016-12-31 | $24.71 Million | $-19.89 Million | -0.805x | -33.49% |
| 2015-12-31 | $22.13 Million | $-13.35 Million | -0.603x | +15.41% |
| 2014-12-31 | $35.64 Million | $-25.41 Million | -0.713x | +86.08% |
| 2013-12-31 | $3.89 Million | $-19.94 Million | -5.121x | -64.90% |
| 2012-12-31 | $9.51 Million | $-29.55 Million | -3.106x | -264.48% |
| 2011-12-31 | $-12.97 Million | $-24.49 Million | 1.888x | +136.58% |
| 2010-12-31 | $2.92 Million | $-15.09 Million | -5.163x | -546.36% |
| 2009-12-31 | $17.28 Million | $-13.80 Million | -0.799x | +4.56% |
| 2008-12-31 | $23.33 Million | $-19.53 Million | -0.837x | -59.46% |
| 2007-12-31 | $28.25 Million | $-14.83 Million | -0.525x | -64.38% |
| 2006-12-31 | $42.34 Million | $-13.52 Million | -0.319x | +4.70% |
| 2005-12-31 | $33.03 Million | $-11.06 Million | -0.335x | +38.07% |
| 2004-12-31 | $17.61 Million | $-9.53 Million | -0.541x | +30.35% |
| 2003-12-31 | $11.57 Million | $-8.99 Million | -0.777x | +4.10% |
| 2002-12-31 | $10.80 Million | $-8.75 Million | -0.810x | -38.68% |
| 2001-12-31 | $10.89 Million | $-6.36 Million | -0.584x | -5.60% |
| 2000-12-31 | $12.44 Million | $-6.88 Million | -0.553x | +57.97% |
| 1999-12-31 | $8.51 Million | $-11.20 Million | -1.316x | +8.75% |
| 1998-12-31 | $10.85 Million | $-15.64 Million | -1.442x | -103.97% |
| 1997-12-31 | $18.81 Million | $-13.30 Million | -0.707x | +11.77% |
| 1996-12-31 | $16.60 Million | $-13.30 Million | -0.801x | +57.74% |
| 1995-12-31 | $4.80 Million | $-9.10 Million | -1.896x | -- |
About Vericel Corp Ord
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the … Read more